The Supreme Court has temporarily extended its order preserving access to mifepristone by mail and telehealth, with Justice Samuel Alito extending the administrative stay until May 14. The dispute stems from Louisiana v. FDA and related emergency applications over the FDA’s 2023 rules.
The U.S. Supreme Court has temporarily extended access to mifepristone, keeping the abortion medication available by mail and through telehealth while the underlying legal fight continues.
Justice Samuel Alito extended an administrative stay on May 11 until 5:00 p.m. EDT on May 14, according to the Court’s docket. The move preserves the status quo for now.
What the order does
The stay blocks new restrictions from taking effect while the Court considers emergency applications in the case. AP reported that the order allows mifepristone to continue being dispensed by mail and through telehealth during the short extension.
The dispute stems from Louisiana v. FDA and related emergency applications filed by Danco Laboratories and GenBioPro.
Why the case matters
The challenge centers on the FDA’s 2023 rules allowing mifepristone to be prescribed without an in-person visit. The drug is widely used in medication abortions in the United States.
Reuters reported that an earlier administrative stay had already restored mail delivery and telehealth access on a temporary basis. Alito’s latest order extends that protection only until Thursday afternoon.
What happens next
The Court has not yet resolved the underlying challenge. The key immediate question is whether the justices will grant a longer stay or allow the restrictions to take effect after May 14.
For now, the practical effect is that access to mifepristone by mail and telehealth remains unchanged for a few more days.
Revision note
Initial automated publication.